EP-4736666-A1 - NUTRIENT COMPOSITION FOR ANIMALS

Abstract

An object of the present invention is to provide a novel animal nutritional composition. The present invention is directed to a racehorse nutritional composition, an animal nutritional composition for reducing an elevation of blood lactic acid concentrations, and an animal nutritional composition for coat improvement, each of which comprises nicotinamide mononucleotide.

Inventors

• IKOMA, Yuki
• YAMANE, TAKUYA

Assignees

• Racehorse Incorporated

Dates

Publication Date

20260506

Application Date

20230629

Claims (4)

1. A racehorse nutritional composition comprising nicotinamide mononucleotide.
2. An animal nutritional composition for reducing an elevation of blood lactic acid concentrations, comprising nicotinamide mononucleotide.
3. An animal nutritional composition for coat improvement, comprising nicotinamide mononucleotide.
4. The animal nutritional composition according to claim 2 or 3, to be used for racehorses.

Description

TECHNICAL FIELD The present invention relates to an animal nutritional composition. BACKGROUND ART Nicotinamide mononucleotide is an intermediate metabolite of coenzyme NAD+ biosynthesis. NPL 1 reports that an oral administration clinical trial on humans demonstrated the action of nicotinamide mononucleotide to improve obesity, prevent diabetes, and improve muscle insulin sensitivity. Moreover, NPL 2 reports that an oral administration test on mice demonstrated the action of nicotinamide mononucleotide to suppress body weight gain, improve insulin sensitivity, improve lipid metabolism, improve eye function, increase bone density, and enhance immune function. However, there is no known reports on orally giving nicotinamide mononucleotide to racehorses. CITATION LIST NON PATENT LITERATURE NPL 1: Mihoko Yoshino, Jun Yoshino, Brandon D Kayser, Gary J Patti, Michael P Franczyk, Kathryn F Mills, Miriam Sindelar, Terri Pietka, Bruce W Patterson, Shin-Ichiro Imai, Samuel Klein, Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women, Science 2021, 372, 1224-1229.NPL 2: Kathryn F. Mills, Shohei Yoshida, Liana R. Stein, Koji Uchida, Jun Yoshino, Shin-ichiro Imai, Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice Cell Metabolism 2016, 24, 795-806. SUMMARY OF INVENTION TECHNICAL PROBLEM An object of the present invention is to provide a novel animal nutritional composition. SOLUTION TO PROBLEM The present invention encompasses the following. [1] A racehorse nutritional composition comprising nicotinamide mononucleotide.[2] An animal nutritional composition for reducing an elevation of blood lactic acid concentrations, comprising nicotinamide mononucleotide.[3] An animal nutritional composition for coat improvement, comprising nicotinamide mononucleotide.[4] The animal nutritional composition according to [2] or [3], to be used for racehorses. ADVANTAGEOUS EFFECTS OF INVENTION The animal nutritional composition according to the present invention makes it possible to reduce an elevation of blood lactic acid concentrations in racehorses and/or improve the coat of racehorses. BRIEF DESCRIPTION OF DRAWINGS Fig. 1 shows results of measurement of lactic acid value concentrations in Test Example 1.Fig. 2 shows average values of lactic acid value concentrations in Test Example 1. DESCRIPTION OF EMBODIMENTS [Nutritional Composition] A nutritional composition according to the present invention (hereinafter also called "the present nutritional composition") contains nicotinamide mononucleotide (hereinafter also called "NMN"). <NMN> NMN (with a chemical formula of C11H15N2O8P) has two optical isomers, α and β, and in the present invention, β-NMN (CAS Number: 1094-61-7) is used. The structure of β-NMN is as follows. The method for preparing β-NMN is not particularly limited. For example, β-NMN synthesized artificially by a chemical synthesis method, an enzymatic method, a fermentation method, and/or the like can be used after purification. Because β-NMN is a component that is found in a wide variety of living things, it is also possible to use β-NMN that is extracted and/or purified from natural sources such as animals, plants, and microorganisms. It is also possible to use commercially-available purified β-NMN. As an example of the chemical synthesis method for synthesizing β-NMN, nicotinamide can be reacted with L-ribose tetraacetate and the resulting nicotinamide mononucleoside can be phosphorylated to produce β-NMN. As an example of the enzymatic method, nicotinamide phosphoribosyltransferase (NAMPT) can be used to produce β-NMN from nicotinamide and 5'-phosphoribosyl-1'-pyrophosphoric acid (PRPP). As an example of the fermentation method, the metabolic pathway of NAMPT-expressing microorganisms can be used to produce β-NMN from nicotinamide. The NMN contained in the present nutritional composition may be a pharmacologically acceptable salt of β-NMN. The pharmacologically acceptable salt of β-NMN may be an inorganic acid salt, or may be an organic acid salt having a basic moiety such as an amine. An acid that forms the above-mentioned acid salt may be, for example, acetic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, ethenesulfonic acid, fumaric acid, gluconic acid, glutamic acid, hydrobromic acid, hydrochloric acid, isethionic acid, lactic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, mucic acid, nitric acid, pamoic acid, pantothenic acid, phosphoric acid, succinic acid, sulfuric acid, tartaric acid, p-toluenesulfonic acid, and/or the like. The pharmacologically acceptable salt of β-NMN may be an alkali salt, and/or may be an organic salt having an acidic moiety such as a carboxylic acid. A base that forms the above-mentioned acid salt may be, for example, an alkali metal salt or an alkaline-earth metal salt, and may be any of those derived from bases such as sodium hydride, potassium h